Murphy & Mullick Capital Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.47M Buy
11,473
+151
+1% +$17.7K 0.91% 25
2026
Q1
$1.36M Buy
11,322
+2,308
+26% +$266K 1.01% 24
2025
Q4
$949K Buy
9,014
+236
+3% +$22.2K 0.68% 32
2025
Q3
$737K Buy
8,778
+532
+6% +$43.8K 0.55% 44
2025
Q2
$651K Sell
8,246
-505
-6% -$40.1K 0.53% 47
2025
Q1
$785K Sell
8,751
-419
-5% -$39.1K 0.76% 33
2024
Q4
$912K Buy
+9,170
New +$945K 0.84% 28

Other funds holding MRK

Murphy & Mullick Capital Management's MRK Position: Q2 2026 in Review

Murphy & Mullick Capital Management increased its Merck (MRK) stake by 1.3% in Q2 2026, buying an estimated $17.7K and bringing the position to 11,473 shares worth $1.47M. The position accounts for 0.91% of the portfolio, ranked #25.

Murphy & Mullick Capital Management first reported a position in MRK in Q4 2024 and has held it in 7 quarters since. 3,844 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Murphy & Mullick Capital Management held 11,473 shares of Merck worth $1.47M as of Q2 2026.
  • Murphy & Mullick Capital Management bought 151 Merck shares in Q2 2026, an estimated $17.7K.
  • Merck made up 0.91% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #25 holding.
  • Murphy & Mullick Capital Management first reported a position in Merck in Q4 2024 and has held it in 7 quarters since.
  • 3,844 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.